Deal Ticker: Kellerhals Carrard advises Panakes Partners in the EUR 17.9 million Series B Financing Round of Lymphatica Medtech

We are thrilled to have advised Panakes Partners in leading the EUR 17.9 million Series B financing round of Lymphatica Medtech! This round was co-led by TechWald Next S.p.A., and CDP Venture Capital’s Digital Transition Fund, with participation from OCCIDENT, Zürcher Kantonalbank, and Club Degli Investitori. Existing investors, including High-Tech Gründerfonds (HTGF), also participated in this round. 

This investment will accelerate the clinical development and validation of LymphoDrain, a breakthrough implantable device designed to treat lymphedema, a chronic vascular condition that currently has no cure and affects millions worldwide. 

We are humbled by the feedback that Alessio Beverina, general partner at Panakes Partners, shared with us: 
“I thank Umberto and the Kellerhals Carrard team for the legal support to Panakes Partners and the new investors group in the Lymphatica Medtech capital increase: they ensure the transaction was smooth and fast, in particular with several parties been part of the agreement, with every detail being meticulously examined and every risk mitigated, crafting every agreement to foster trust and clarity.” 

We wish Panakes Partners a fruitful collaboration with the company and look forward to witnessing their continued success. 

The Kellerhals Carrard team was co-led by Karim Maizar (Partner, VC/M&A) and Umberto Milano (Senior Associate, VC/M&A) and further included Céline Schmid (Senior Associate, Employment), Eliane Haas (Senior Associate, IP), Eckert Arnault (Associate, VC/M&A) and Céline Reust (Trainee). 

Here’s to many more achievements ahead!